retatrutide phase 2 trial results weight loss Results:Trial Data and FDA Status Retatrutide Phase 2 vs Phase

The following flow antibodies were used: anti-mouse CD4 PE/Cy7 (clone GK1.5) (BioLegend, 100422), anti-mouse IL-17a PE (clone TC11-1810.1) (BioLegend, 506903), anti-mouse CD45 PerCP/Cy5.5 (clone 30-F11) (BioLegend,103131), anti-mouse GATA3 (BioLegend, 653809), antimouse/human CD11b PE/Cy7 (clone M1/70) (BioLegend, 101216), anti-mouse/human CD11b Brilliant Violet 605 (clone M1/70) (BioLegend, 101237), antimouse inducible NO synthase (iNOS) (Invitrogen, 125920), antimouse Foxp3 Pacific blue (clone MF-14) (BioLegend, 26410), antimouse/human Arg1 FITC (R&D Systems, IC5868F), anti-mouse F4/80 PerCP/Cy5.5 (clone BM8) (BioLegend, 123127), antimouse MGL2/CD301B (BioLegend, 146807), antimouse/human T-bet PE/Cy7 (clone 4B10) (Biolegend, 644824), antimouse/human RORt (APC, clone AFKJS-9) (Invitrogen, 17698882), antimouse Ly6G (clone 1A8) (BioLegend, 127613), and PE antimouse CD206 (clone C068C2) (BioLegend, 141705)

According to the FDA prescribing label, reactions such as injection-site discomfort and erythema (redness) were reported in placebo-controlled trials

Description Additional information Reviews (0) Attachment Description Research PeptideTri-AgonistLot Verified GL -3 RT Triple-Receptor Research Peptide A next-generation synthetic peptide engineered as a unimolecular agonist of three metabolic receptors simultaneously a new frontier in metabolic and obesity research

Case No.: 3:25-cv-05315 Jurisdiction : U.S

All tests were 2-sided, and differences resulting in P 3.0.CO;2-A